Pipeline

Our Pipeline of Product Candidates

We have discovered a novel pipeline of human monoclonal antibody candidates that are based on the protective immune responses generated by patients who have been vaccinated against selected cancers with our proprietary vaccines.

Program Collaborators Discovery Pre-IND Phase 1
Radioimmunotherapy (MVT-1075) Sialyl Lewisa for Pancreatic Cancer and CA19-9 malignancies including Lung and GI Cancers MSKCC
Discovery Phase complete
Pre-IND Phase complete
Phase 1 Phase in progress
Therapeutic (MVT-5873) Monotherapy Sialyl Lewisa for Pancreatic Cancer and CA19-9 malignancies including Lung and GI Cancers NIH, MSKCC, SCRI, Patheon
Discovery Phase complete
Pre-IND Phase complete
Phase 1 Phase in progress
ImmunoPET Imaging (MVT-2163) Sialyl Lewisa for Pancreatic Cancer and CA19-9 malignancies including Lung and GI Cancers NIH, MSKCC, SCRI, Patheon
Discovery Phase complete
Pre-IND Phase complete
Phase 1 Phase in progress
Therapeutic (MVT-5873) + Chemo Metastatic Pancreatic Cancer and CA19-9 malignancies including Lung and GI Cancers MSKCC
Discovery Phase complete
Pre-IND Phase complete
Phase 1 Phase in progress
HuMab-Tn Breast and Ovarian Cancer MSKCC
Discovery Phase complete
Pre-IND Phase in progress
Phase 1 Phase not started
CAR-T-Sialyl Lewisa MSKCC
Discovery Phase in progress
Pre-IND Phase not started
Phase 1 Phase not started
CAR-T-GD2 MSKCC
Discovery Phase in progress
Pre-IND Phase not started
Phase 1 Phase not started
Commercial Rights: WW

Tumor Targeting Capabilities with HuMab-5B1

Our HuMab-5B1 antibody is fully human and was discovered from the immune response of cancer patients vaccinated with an antigen-specific vaccine during a Phase 1 trial at Memorial Sloan Kettering Cancer Center. In preclinical research, the 5B1 antibody has demonstrated high specificity and affinity, and has shown potent cancer cell killing capacity and efficacy in animal models of pancreatic, colon and small cell lung cancers. The antigen the antibody targets is expressed on more than 90% of pancreatic cancers and a significant percentage of other GI and lung cancers, making the antibody potentially broadly applicable to a wide variety of patients suffering from difficult to treat cancers.

The HuMab-5B1 antibody has very good tumor targeting capabilities and is internalized by pancreatic cancer cells. These important attributes have allowed us to use the HuMab-5B1 antibody as a tumor-targeting platform to create multiple products. The antibody itself has completed a Phase 1a clinical trial as a therapeutic agent. This same antibody, when combined with a radiolabel, is a potentially new generation PET imaging agent, which has also completed a Phase 1a clinical trial. We are also developing more potent HuMab-5B1 based products such as our lead program, a radioimmunotherapy product, where the antibody is combined with a cytotoxic radioisotope, and lastly, an antibody drug conjugate when combined with a toxin payload. While all of the mentioned products are based on the targeting capabilities of HuMab-5B1, each product has unique characteristics and potential uses for the treatment of multiple types of solid tumors.

Therapeutic (MVT-5873)

MVT-5873 is the clinical designation for the HuMab-5B1 antibody as a single agent therapeutic product. We initiated the MVT-5873 therapeutic trial to evaluate the safety, tolerability and pharmacokinetics of HuMab-5B1 as a single agent or in combination with the current standard of care chemotherapy regimen in subjects with metastatic pancreatic cancer.

View Candidate

ImmunoPET Imaging (MVT-2163)

MVT-2163 is the clinical designation for the HuMab-5B1 antibody combined with a 89Zirconium radiolabel as a immunoPET diagnostic product. We initiated the MVT-2163 PET imaging trial at Memorial Sloan Kettering. This new PET agent can potentially be an important new tool to aid in the diagnosis, monitoring and assessment of pancreatic cancer patients and a companion diagnostic for the MVT-5873 therapeutic product.

View Candidate

Radioimmunotherapy (MVT-1075)

MVT-1075 is the clinical designation for the HuMab-5B1 antibody combined with the clinically proven radionuclide, 177Lutetium, as a radioimmunotherapy product. The radioimmunotherapy product is designed to target pancreatic cancer cells and kill them by localized, target specific irradiation.

View Candidate